Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Cotrimoxazole alters circulating CD4+ T cell phenotype in HIV infection.
  • Fig. S2. Fecal bacterial species that differ between HIV-positive ART-treated Zimbabwean children randomized to continue versus stop cotrimoxazole prophylaxis.
  • Fig. S3. Protein families that differ between stool samples from HIV-positive ART-treated Zimbabwean children randomized to continue versus stop cotrimoxazole prophylaxis.
  • Fig. S4. Fecal biomarkers of enteropathy that were unaffected by continuing versus stopping cotrimoxazole prophylaxis.
  • Fig. S5. Associations between all fecal bacterial species that differed between HIV-positive children randomized to continue versus stop cotrimoxazole prophylaxis and fecal myeloperoxidase.
  • Fig. S6. Associations between all fecal Pfam that differed between HIV-positive children randomized to continue versus stop cotrimoxazole prophylaxis and fecal myeloperoxidase.
  • Fig. S7. Optimization of in vitro blood leukocyte activation and cotrimoxazole treatment conditions.
  • Fig. S8. HIV-positive adults have greater systemic inflammation, monocyte, and T cell activation than HIV-negative adults.
  • Fig. S9. Flow cytometry gating strategy for analysis of monocyte and T cell intracellular cytokine responses.
  • Table S1. Characteristics of HIV-negative and HIV-positive UK adult volunteers.
  • Table S2. Details of fluorophore-conjugated antibody combinations used for flow cytometry analysis of PBMC from HIV-negative and HIV-positive adults.
  • References (6468)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: